ATE481645T1 - Biomarker für den frühzeitigen nachweis von ovarialkarzinom - Google Patents

Biomarker für den frühzeitigen nachweis von ovarialkarzinom

Info

Publication number
ATE481645T1
ATE481645T1 AT05771584T AT05771584T ATE481645T1 AT E481645 T1 ATE481645 T1 AT E481645T1 AT 05771584 T AT05771584 T AT 05771584T AT 05771584 T AT05771584 T AT 05771584T AT E481645 T1 ATE481645 T1 AT E481645T1
Authority
AT
Austria
Prior art keywords
stage
patients
ovarian
biomarrkers
early detection
Prior art date
Application number
AT05771584T
Other languages
English (en)
Inventor
Robin Farias-Eisner
Srinivasa Reddy
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Application granted granted Critical
Publication of ATE481645T1 publication Critical patent/ATE481645T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57545—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the ovaries
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/72—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
    • G01N33/721—Haemoglobin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/78—Thyroid gland hormones, e.g. T3, T4, TBH, TBG or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/775—Apolipopeptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/79—Transferrins, e.g. lactoferrins, ovotransferrins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT05771584T 2004-07-14 2005-07-14 Biomarker für den frühzeitigen nachweis von ovarialkarzinom ATE481645T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US58800704P 2004-07-14 2004-07-14
US67448905P 2005-04-25 2005-04-25
PCT/US2005/024985 WO2006019906A1 (en) 2004-07-14 2005-07-14 Biomarker for early detection of ovarian cancer

Publications (1)

Publication Number Publication Date
ATE481645T1 true ATE481645T1 (de) 2010-10-15

Family

ID=35406265

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05771584T ATE481645T1 (de) 2004-07-14 2005-07-14 Biomarker für den frühzeitigen nachweis von ovarialkarzinom

Country Status (6)

Country Link
US (3) US8323915B2 (de)
EP (5) EP2199801B1 (de)
AT (1) ATE481645T1 (de)
DE (1) DE602005023629D1 (de)
DK (1) DK2199801T3 (de)
WO (1) WO2006019906A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012047930A2 (en) 2010-10-04 2012-04-12 The Regents Of The University Of California Compositions and methods for treatment of gynecologic cancers
US9488655B2 (en) * 2004-07-14 2016-11-08 The Regents Of The University Of California Biomarkers for detection of early- and late-stage endometrial cancer
CN101243319B (zh) * 2005-06-22 2016-01-06 约翰·霍普金斯大学 卵巢癌的生物标记：ctap3-相关蛋白质
RU2313794C1 (ru) * 2006-06-06 2007-12-27 Людмила Васильевна Дикарева Способ дифференциальной диагностики опухолевых процессов яичников
EP2210099A4 (de) 2007-03-27 2011-03-16 Vermillion Inc Biomarker für ovarialkarzinom
KR100997463B1 (ko) * 2007-04-30 2010-11-30 (주)예비티 난소암 진단용 조성물, 그 키트 및 진단 방법
RU2334986C1 (ru) * 2007-05-28 2008-09-27 Евгений Григорьевич Шварев Способ ранней диагностики опухолей яичников
EP2220506B1 (de) * 2007-10-29 2013-10-02 Vermillion, Inc. Biomarker zum nachweis von ovarialkarzinom im frühstadium
WO2011128892A2 (en) * 2010-04-12 2011-10-20 Protea Vaccine Technologies Ltd. Modified forms of pneumococcal surface immunogenic protein b (psipb)
CA2818593A1 (en) * 2010-10-22 2012-04-26 Vermillion, Inc. Prognostic biomarkers in patients with ovarian cancer
US9406848B2 (en) * 2011-06-10 2016-08-02 Basf Se Color converter
US9241976B2 (en) 2011-08-29 2016-01-26 The Regents Of The University Of California Use of HDL-related molecules to treat and prevent proinflammatory conditions
KR20150127587A (ko) * 2013-03-15 2015-11-17 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 결핵의 예방 또는 치료를 위한 합성 면역원
US20150153348A1 (en) * 2013-12-04 2015-06-04 Vermillion, Inc. BIOMARKERS FOR OVARIAN CANCER: Beta 2 MICROGLOBULIN
RU2576821C2 (ru) * 2014-06-30 2016-03-10 Федеральное государственное бюджетное учреждение "Московский научно-исследовательский онкологический институт им. П.А. Герцена Министерства здравоохранения Российской Федерации" (ФГБУ "МНИОИ им. П.А. Герцена" Минздрава России) Способ определения эффективности консервативного лечения рака не увеличенных яичников

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US4918164A (en) 1987-09-10 1990-04-17 Oncogen Tumor immunotherapy using anti-idiotypic antibodies
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
DK145385D0 (da) * 1985-03-29 1985-04-01 Novo Industri As Monoklonalt antistof til immunkemisk analyse
GB8508845D0 (en) 1985-04-04 1985-05-09 Hoffmann La Roche Vaccinia dna
US4777127A (en) 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US5114863A (en) * 1986-09-30 1992-05-19 Board Of Supervisors Of Louisiana State University & Agricultural & Mechanical College Immunosorbant assay for α-1-antitrypsin, kit employing said assay, monoclonal antibody to α-1-antitrypsin, and hybridoma for producing said monoclonal antibody
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
GB8702816D0 (en) 1987-02-07 1987-03-11 Al Sumidaie A M K Obtaining retrovirus-containing fraction
US4897268A (en) 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
WO1989001973A2 (en) 1987-09-02 1989-03-09 Applied Biotechnology, Inc. Recombinant pox virus for immunization against tumor-associated antigens
EP0398880A4 (en) 1988-01-04 1990-12-27 E.I. Du Pont De Nemours And Company Multiple stage affinity process for isolation of specific cells from a cell mixture
US5215926A (en) 1988-06-03 1993-06-01 Cellpro, Inc. Procedure for designing efficient affinity cell separation processes
AP129A (en) 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
US5536475A (en) 1988-10-11 1996-07-16 Baxter International Inc. Apparatus for magnetic cell separation
AU648261B2 (en) 1989-08-18 1994-04-21 Novartis Vaccines And Diagnostics, Inc. Recombinant retroviruses delivering vector constructs to target cells
SE8904007D0 (sv) * 1989-11-28 1989-11-28 Ferring Ab Monoklona antikroppar och diagnostiseringsmetod
WO1991016116A1 (en) 1990-04-23 1991-10-31 Cellpro Incorporated Immunoselection device and method
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
CA2094258A1 (en) 1990-10-18 1992-04-19 Dale Kalamasz An apparatus and method for separating particles using a pliable vessel
US5240856A (en) 1991-10-23 1993-08-31 Cellpro Incorporated Apparatus for cell separation
US6277603B1 (en) 1991-12-24 2001-08-21 Isis Pharmaceuticals, Inc. PNA-DNA-PNA chimeric macromolecules
US5700922A (en) 1991-12-24 1997-12-23 Isis Pharmaceuticals, Inc. PNA-DNA-PNA chimeric macromolecules
US20030027216A1 (en) * 2001-07-02 2003-02-06 Kiernan Urban A. Analysis of proteins from biological fluids using mass spectrometric immunoassay
EP0871747A1 (de) 1996-01-02 1998-10-21 Chiron Viagene, Inc. Immunstimulierung vermittelt durch genmodifizierte dendritische zellen
CA2722378C (en) 1996-12-03 2015-02-03 Amgen Fremont Inc. Human antibodies that bind tnf.alpha.
US5891641A (en) * 1997-02-21 1999-04-06 The Regents Of The University Of California Assay for disease related conformation of a protein
NZ516848A (en) 1997-06-20 2004-03-26 Ciphergen Biosystems Inc Retentate chromatography apparatus with applications in biology and medicine
US5955582A (en) * 1997-09-26 1999-09-21 Beckman Coulter, Inc. Antibody against a 3-aminophenylboronic-glycated protein complex and its use in an immunoassay
GB9805877D0 (en) * 1998-03-20 1998-05-13 Imp Cancer Res Tech Cancer
DE69940479D1 (de) * 1998-12-22 2009-04-09 Daiichi Pure Chemicals Co Ltd Monoklonaler antikörper gegen apolipoprotein a-i
EP1384079A2 (de) * 2001-05-02 2004-01-28 Oxford GlycoSciences (UK) Limited Proteinen, genen und ihre verwendung zur diagnose und behandlung von brustkrebs
US20050214760A1 (en) * 2002-01-07 2005-09-29 Johns Hopkins University Biomarkers for detecting ovarian cancer
AU2003247610A1 (en) * 2002-06-21 2004-01-06 Ptc Therapeutics, Inc. METHODS FOR IDENTIFYING SMALL MOLECULES THAT MODULATE PREMATURE TRANSLATION TERMINATION AND NONSENSE MEDIATED mRNA DECAY
AU2003244817B2 (en) * 2002-06-28 2010-08-26 Domantis Limited Antigen-binding immunoglobulin single variable domains and dual-specific constructs
AU2003252136A1 (en) * 2002-07-24 2004-02-09 Ptc Therapeutics, Inc. METHODS FOR IDENTIFYING SMALL MOLEDULES THAT MODULATE PREMATURE TRANSLATION TERMINATION AND NONSENSE MEDIATED mRNA DECAY
KR101107765B1 (ko) * 2002-08-06 2012-01-25 싸이퍼젠 바이오시스템즈, 인코포레이티드 난소암의 검출을 위한 생물 마커의 용도
US7191068B2 (en) * 2003-03-25 2007-03-13 Proteogenix, Inc. Proteomic analysis of biological fluids
WO2004101766A2 (en) * 2003-05-12 2004-11-25 The Children's Hospital Of Philadelphia Grp94-based compositions and methods of use thereof
WO2005019820A1 (en) * 2003-08-25 2005-03-03 Marc Ramael A method and kit for the quantitative and/or qualitative detection of components in a sample
EP1713900A4 (de) * 2004-01-27 2009-06-17 Compugen Ltd Verfahren und systeme zur kommentierung biomolekularer sequenzen
WO2005093413A2 (en) * 2004-03-22 2005-10-06 Yale University Diagnosis and treatment of preeclampsia
US20050250141A1 (en) * 2004-03-30 2005-11-10 Lambert James L Diagnostic assays including multiplexed lateral flow immunoassays with quantum dots
EP1799861A2 (de) * 2004-09-20 2007-06-27 Proteogenix, Inc. Diagnose einer fötalen aneuploidie
US7510842B2 (en) * 2005-03-11 2009-03-31 Vermilllion, Inc. Biomarker for ovarian and endometrial cancer: hepcidin
WO2006121952A2 (en) * 2005-05-05 2006-11-16 The Regents Of The University Of California Diagnostic biomarkers for neurodevelopmental disorders
US7575876B2 (en) * 2005-10-27 2009-08-18 The University Of Washington Biomarkers for neurodegenerative disorders

Also Published As

Publication number Publication date
US20160069886A1 (en) 2016-03-10
EP2261672A3 (de) 2011-10-05
EP1789805A1 (de) 2007-05-30
EP2261672B1 (de) 2014-09-03
EP3203241A1 (de) 2017-08-09
EP2199801A3 (de) 2010-08-25
EP2848942A1 (de) 2015-03-18
US8323915B2 (en) 2012-12-04
US9110083B2 (en) 2015-08-18
DE602005023629D1 (de) 2010-10-28
EP2199801B1 (de) 2013-05-29
EP2848942B1 (de) 2017-03-08
US20130090256A1 (en) 2013-04-11
EP2261672A2 (de) 2010-12-15
WO2006019906A1 (en) 2006-02-23
EP1789805B1 (de) 2010-09-15
DK2199801T3 (da) 2013-08-05
US20100081151A1 (en) 2010-04-01
EP2199801A2 (de) 2010-06-23

Similar Documents

Publication Publication Date Title
ATE481645T1 (de) Biomarker für den frühzeitigen nachweis von ovarialkarzinom
ATE365922T1 (de) Verfahren zur erkennung von eierstockkrebs mittels menschlichem kallikrein (hk6)
Torphy et al. Circulating tumor cells as a biomarker of response to treatment in patient-derived xenograft mouse models of pancreatic adenocarcinoma
ATE386938T1 (de) Ykl-40 als marker und indikator zur prognose von krebs und detektion von infektionen
Vail et al. Telomerase reverse transcriptase promoter mutations in glandular lesions of the urinary bladder
WO2003021227A3 (en) Methods and compositions useful for diagnosis, staging, and treatment of cancers and tumors
ATE553382T1 (de) Verwendungen von krebsspezifischen glykanen
CA2701341A1 (en) Method of assessing colorectal cancer from a stool sample by use of the marker combination calprotectin and hemoglobin/haptoglobin complex
Bernacki et al. The utility of PSMA and PSA immunohistochemistry in the cytologic diagnosis of metastatic prostate carcinoma
ATE522620T1 (de) Nachweis von micrometastasierung von melanomen und brustkrebs an in paraffin eingegbetteten, von tumoren abführenden lymphknoten mittels quantitativer multimaker rt-pcr
Chia et al. Utility of mammaglobin and gross cystic disease fluid protein-15 (GCDFP-15) in confirming a breast origin for recurrent tumors
MY193895A (en) Combination test for colorectal cancer
SG165370A1 (en) Method for the diagnosis of colorectal cancer and ovarian cancer by the measurement of vitamin e-related metabolites
WO2003021229A3 (en) Diagnostic and prognostic tests
DE602005014386D1 (de) Verwendung von cyfra 21-1 und osteopontin als marker für kolorektalkarzinome
Kato et al. Serum cytokeratin 19 fragment 21‐1 is a useful tumor marker for the assessment of extramammary Paget's disease
ATE479898T1 (de) Reagenzien und verfahren zur verwendung bei der diagnose, klassifizierung und behandlung von krebs
DE60335387D1 (de) Zusammensetzungen und deren verwendungen zur identifizierung und zum targetting von provasopressinexprimierenden krebszellen
DE602004022632D1 (de) Verwendung von adiponectin zur diagnose von krebs
Banakar et al. Oral squamous cell carcinoma: the role of BIRC6 serum level
Chen et al. Concordance of PD-L1 expression in triple-negative breast cancers in Chinese patients: A retrospective and pathologist-based study
Kang et al. Prognostic role of neutrophil-to-lymphocyte ratio-based markers during pre-and postadjuvant chemotherapy in patients with advanced urothelial carcinoma of upper urinary tract
DE602005023329D1 (de) VERFAHREN ZUR DIAGNOSE NICHT-KLEINZELLIGER LUNGENKARZINOME ÜBER DIE tRNA-DIHYDROURIDIN-SYNTHASEAKTIVITÄT VON URLC8
DE60025342D1 (de) Komplex aus n-glykolisierten proteinen (siblings) und faktor h
FI20155098A7 (fi) Immunokemiallinen ulosteen testi kolorektaalisen neoplasian seulomiseksi

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties